ZebraSci - Combination Product Experts

ZebraSci - Combination Product Experts
Product Description

ZebraSci supports your combination product development from concept to market. ZebraSci was founded in 2009 as a company dedicated to developing novel inspection technologies to ensure quality in parenteral packaging and combination products. Over the years, we’ve grown substantially by concentrating on technical expertise, customer service and a strict adherence to regulatory compliance. As an independent combination testing and expert advisory platform our goal is to challenge the limits and cultivate unique solutions for our customers. We also leverage the knowledge from our past and the structure of our parent company to expand our capabilities. This has allowed us to continue to test products outside of the BD portfolio while also giving clients an opportunity to gain access to both product and service needs. Our goal is to challenge the limits of this industry and cultivate unique solutions for our customers.

Read more Show less

ZebraSci Inc.

  • US
  • 2022
    On CPHI since
  • 1
    Certificates
  • 1 - 24
    Employees
Company types
Contract Service
Primary activities
Laboratory Services
View company profile

ZebraSci Inc.

  • US
  • 2022
    On CPHI since
  • 1
    Certificates
  • 1 - 24
    Employees
Company types
Contract Service
Primary activities
Laboratory Services
View company profile

ZebraSci Inc. resources (3)

  • Supporting your combination product development from concept to market

    Brochure Supporting your combination product development from concept to market

    Streamlined Solutions. Dependable Service. Technical Expertise.
  • Challenges of Extractables & Leachables Experience

    Webinar Challenges of Extractables & Leachables Experience

    The investigation of the chemical compatibility between a drug product and its container relates to drug product quality, efficacy and safety - critical parameters for the development and commercialisation of a drug product. This implies assessing the extractables and leachables for each new drug product before submission for marketing authorization, and to re-evaluate requirements for each variation of an existing drug product. A 'Toxicological Risk Assessment' must also be conducted to evaluate patient exposure to chemicals over shelf-life and it is the responsibility of a Pharmaceutical company to provide timely evidence on the quality of their finished product. Tools & methodology for E&L studies can be deployed to anticipate challenges and provide key data to de-risk your drug combination product development, even at an early stage.
    2024-02-02
  • Container Closure Integrity (CCI) Testing

    Webinar Container Closure Integrity (CCI) Testing

    In this webinar, originally broadcast as part of the Pharmapack Europe show, Robert Schultheis, Founder & Chief Technology Officer, ZebraSci discusses: Probabilistic vs deterministic CCI Testing Presentation of the different deterministic CCI testing methods with applications and limitations What to consider when selecting CCI testing method In this session the audience will benefit from understanding the influence of the drug specificities to select the most suitable technical option for Container Closure Integrity testing activitiesbased on the advantages and limitations of different techniques available on the market
    2023-01-24

Recommended Products

Recently Visited